ORLADEYO
berotralstatsmall moleculeplasma kallikrein inhibitor
Hereditary Angioedema
Approved
1 program·0 trials·View drug →
DashboardOption ex.4,804$21.18$101.8KAward8,415$22.39$188.5KSell14,496$18.56−$269.0KSell9,330$21.23−$198.0K Internal MedicineCo-Investigator$391.0K6Pediatric Rare DiseaseEquity / Ownership$333.3K4GeneticsResearch Grant$117.1K4Pediatric Rare DiseaseEquity / Ownership$109.1K3Internal MedicineConsulting$31.5K5
BCRXNASDAQ
BioCryst
BioCryst Pharmaceuticals, Inc. · Durham, NC · founded 1986
BioCryst Pharmaceuticals is a Durham, North Carolina biotech that designs small-molecule drugs from the protein structure outward — using structure-based discovery to optimize how a candidate fits its target. The commercial product ORLADEYO (berotralstat) is the first oral once-daily therapy to prevent attacks of hereditary angioedema (HAE), and the pipeline targets additional rare immunological and complement-mediated diseases.
- Lead asset
- ORLADEYO · Approved · Hereditary Angioedema
- small molecule · plasma kallikrein inhibitor
- Pipeline
- 1 drug · 1 program
- 1 Immunology
- Modalities
- small molecule×1
FocusRare DiseaseImmunology
$7.70+9.84%1Y
BCRX · daily close · illustrative · 1 catalyst marked
Conf.+9%
1Y high$7.901Y low$6.33range$1.57(25%)past catalysts
Peers in this space
REGN$76.0B
Regeneron
Rel.
0.77
ImmunologymAb
1 programmatch: sector
IMVT$5.7B
Immunovant
Rel.
0.46
ImmunologymAb
1 programmatch: sector
NTLA$1.9B
Intellia
Rel.
0.31
Immunologygene therapy
1 programmatch: sector
BMY$105.0B
Bristol Myers Squibb
Rel.
0.65
Cardiology - HFpEFsmall molecule
1 programmatch: modality
INCY$14.6B
Incyte
Rel.
0.72
Oncology - Hemesmall molecule
1 programmatch: modality
MDGL$6.8B
Madrigal
Rel.
0.57
NASH / MASHsmall molecule
1 programmatch: modality
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph30
- Filed0
- Approved1
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Sep 27, 2025Conf.ORLADEYO — ASH Late-Breaker — Updated SurvivalPositive+9.4%+4.6%+8.4%
Sep 2, 2024Conf.ORLADEYO — ASH Late-Breaker — Updated SurvivalPositive+5.8%+8.6%+8.7%
Jul 4, 2024PDUFAORLADEYO — PDUFA — CRL IssuedMixed+34.8%+45.2%+37.3%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 6 transactions · 6 insiders
3 near a catalyst
Net flow
−$1.0M
Buys
$439.6K
1 txns
Sells
$1.5M
3 txns
Largest
−$1.0M
CFO sell
Net flow per quarter · last 8Q
10 txns · sum −$2.59M
24Q325Q125Q326Q126Q2
buys · $440Ksells · $3.03M
Insider · roleActionSharesPriceValueDate
J. Kim
EVP
Apr 23, 2026
E. Park
CFO
Mar 31, 2026
J. Tanaka
CSO
Mar 6, 2026
S. O'Connor
EVP
Mar 5, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
5 trades · 5 members
Est. net flow
−$483K
midpoint · brackets only
Buys
1
Sells
4
Party mix
3 D2 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
D
Sell$250K–$500K~$375KjointRep. H. Patel
House · IL
Dec 6, 2025
filed +40d
R
Partial sell$50K–$100K~$75KselfRep. J. Calhoun
House · GA
Sep 20, 2025
filed +26d
D
Sell$15K–$50K~$33KspouseRep. K. Linville
House · WA
Sep 20, 2025
filed +7d
D
Buy$15K–$50K~$33KspouseRep. L. Marquez
House · NM
Aug 29, 2025
filed +21d
R
Sell$15K–$50K~$33KspouseSen. D. Greenwood
Senate · TX
Jun 27, 2025
filed +10d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
3 ETFs hold the position
Held by ETFs
$1.6M
aggregate position
Of market cap
0.10%
aggregate ETF share
Top holder
BBC1.42%
Virtus LifeSci Biotech Clinical Trials
TickerETF · familyThemeNAV% of NAVPosition
BBCSmall-cap biotech$60.0M1.42%$852K
Virtus LifeSci Biotech Clinical Trials
WisdomTree
SBIOSmall-cap biotech$110.0M0.50%$550K
ALPS Medical Breakthroughs ETF
First Trust
PBEBroad biotech$175.0M0.14%$245K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
5 physicians paid · 22 disclosed records
Total 2025+2024
$982.1K
YoY
+80%
Equity / Ownership$465.8KCo-Investigator$285.3KConsulting$156.9KResearch Grant$57.8KTravel & Lodging$12.8KSpeaking$3.0KFood & Beverage$585
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Henry O'Connor
MD Anderson
Dr. Liam Patel
Stanford Medicine
Dr. Sarah Reyes
Mayo Clinic
Dr. James Nakamura
Johns Hopkins
Dr. Rebecca Greene
Penn Medicine
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
No lobbying disclosures filed with the Senate LDA database in window.
Government contracts
Federal contracts · USAspending.gov
1 award · 1 agency
Total awarded
$2.6M
across all programs
Active
$2.6M
option periods incl.
Top agency
NIH / NCI$2.6M
largest active: Rare Cancer Translational Research Grant
AgencyTitle · type · award IDStatusValueAwarded → ends
NIH / NCIactive$2.6MAug 2024→ Dec 2027
Rare Cancer Translational Research Grant
Grant · NIH-88817888
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
2 granted · 5 pending
Total in portfolio
7
Granted in last 12mo
0
Expiring < 2yr
0
Nearest expiry
Apr 2031
Patent #Title · inventor · drugTypeStatus · filedExpiry
US 2026/6296374 A1Process
Purification methods for ORLADEYO
F. Davies + 4 · ORLADEYO
pendingfiled Apr 2026
in prosecution
US 2025/4594202 A1Composition of Matter
Bispecific antibody compositions targeting ORLADEYO
B. Reyes + 4 · ORLADEYO
pendingfiled Apr 2025
in prosecution
US 2025/0428580 A1Formulation
Pre-filled syringe formulations comprising ORLADEYO
J. Walsh + 4 · ORLADEYO
pendingfiled Apr 2025
in prosecution
US 2021/4930395 A1Composition of Matter
Genome editing constructs encoding ORLADEYO
K. Voss + 1 · ORLADEYO
pendingfiled Apr 2021
in prosecution
US 2019/3030615 A1Composition of Matter
Antibody-drug conjugates with novel linkers for ORLADEYO
K. Davies + 4 · ORLADEYO
pendingfiled Apr 2019
in prosecution
12,457,845Method of Use
Methods of treating advanced disease using ORLADEYO
J. Goldstein + 2 · ORLADEYO
grantedfiled Apr 2014
exp. Apr 2034
8.0y left
11,764,355Method of Use
Methods of treating advanced disease using ORLADEYO
K. Davies · ORLADEYO
grantedfiled Apr 2011
exp. Apr 2031
5.0y left
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
4 items from 3 categories
partnership2analyst1regulatory1
13d ago
BCRX expands co-development partnership for next-gen pipeline
Business Wire·partnership
1mo ago
BCRX enters licensing agreement with major pharma for ORLADEYO
Business Wire·partnership
1mo ago
Bank reiterates Outperform rating on BCRX
Reuters·analyst
1mo ago
BCRX receives Orphan Drug Designation for ORLADEYO
FierceBiotech·regulatory
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$7.70
Open
$7.72
Day Δ
-0.02
-0.26%
Day range
$7.65 – $7.77
52W range
$6.33 – $7.90
Avg daily volume
1.99M
Valuation & ownership
Enterprise value
$1.4B
Shares out
207.79M
Float
182.86M
Insider %
7.23%
Institutional %
82.23%
Beta
2.23
vs SPY · 52w
Balance sheet & burn
Cash + invest
$443M
Total debt
$23M
Debt / equity
4.23
Cash burn / Q
$46M
R&D spend TTM
$175M
40% of cash
ATM available
None
no active facility
Earnings
EPS latest
$-0.38
EPS Δ vs prior
+0.03
EPS estimate
$-0.45
next quarter
EPS prior
$-0.41
Next earnings
Jun 20, 2026
Rev guidance
$13M